Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 1;74(5):1311-1316.
doi: 10.1093/jac/dkz012.

Evaluation of apramycin against spectinomycin-resistant and -susceptible strains of Neisseria gonorrhoeae

Stefan Riedel  1   2 , Divya Vijayakumar  3 , Gretchen Berg  1 , Anthony D Kang  1   4 , Kenneth P Smith  1   2 , James E Kirby  1   2
Affiliations

Evaluation of apramycin against spectinomycin-resistant and -susceptible strains of Neisseria gonorrhoeae

Stefan Riedel et al. J Antimicrob Chemother. .

Abstract

Background: The emergence of Neisseria gonorrhoeae resistant to all currently available antimicrobial therapies poses a dire public health threat. New antimicrobial agents with activity against N. gonorrhoeae are urgently needed. Apramycin is an aminocyclitol aminoglycoside with broad-spectrum in vitro activity against MDR Gram-negative pathogens and Staphylococcus aureus. However, its activity against N. gonorrhoeae has not been described.

Objectives: The activity spectrum of apramycin against a collection of MDR N. gonorrhoeae was assessed. Isolates tested included those susceptible and resistant to the structurally distinct aminocyclitol, spectinomycin.

Results: The modal MICs for apramycin and spectinomycin were 16 mg/L and 32 mg/L, respectively. The epidemiological cut-off (ECOFF) for apramycin was 64 mg/L. No strains among 77 tested had an MIC above this ECOFF, suggesting very low levels of acquired apramycin resistance. In time-kill analysis, apramycin demonstrated rapid bactericidal activity comparable to that of spectinomycin.

Conclusions: Apramycin has broad-spectrum, rapidly bactericidal activity against N. gonorrhoeae. Future pharmacokinetic and pharmacodynamic studies will be needed to determine whether apramycin and/or apramycin derivatives hold promise as new therapeutics for N. gonorrhoeae infection.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Apramycin and spectinomycin MIC distribution for N. gonorrhoeae.
Figure 2.
Figure 2.
Time–kill analysis. Apramycin (APR) and spectinomycin (SPT) were tested against various strains (MIC values are indicated in parentheses in panel titles). A ‘no antibiotic’ control and a doubling dilution series of increasing concentrations tested (mg/L) are indicated, respectively, by filled circles, open squares, open triangles, open inverted triangles, open diamonds and open circles. Specific concentrations tested (mg/L) are indicated in respective panel legends. Both apramycin and spectinomycin were bactericidal. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
See this image and copyright information in PMC

References

    1. Newman L, Rowley J, Vander Hoorn S. et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One 2015; 10: e0143304.. - PMC - PubMed
    1. Lewis DA. The Gonococcus fights back: is this time a knock out? Sex Transm Infect 2010; 86: 415–21. - PubMed
    1. Tapsall JW, Ndowa F, Lewis DA. et al. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009; 7: 821–34. - PubMed
    1. Unemo M, Nicholas RA.. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012; 7: 1401–22. - PMC - PubMed
    1. Cole MJ, Chisholm SA, Hoffmann S. et al. European surveillance of antimicrobial resistance in Neisseria gonorrhoeae. Sex Transm Infect 2010; 86: 427–32. - PubMed

Publication types

MeSH terms